Please login to the form below

Ultomiris

This page shows the latest Ultomiris news and features for those working in and with pharma, biotech and healthcare.

Apellis jumps as pegcetacoplan tops Alexion’s Soliris in PNH trial

with C5 inhibitor Soliris and Alexion’s follow-up Ultomiris (ravulizumab), which brought in $990m and $90m respectively in the third quarter of 2019. ... Alexion was quick to point out that the standard treatment for PNH is shifting from Soliris to

Latest news

Alexion eyes Soliris combo with $930m deal to buy Achillion

Both Achillion’s drugs could be used in combination with Soliris as well as Alexion’s longer-acting follow-up drug Ultomiris (ravulizumab) in PNH – a life-threatening disorder in which
Amgen takes aim at Alexion’s patents for Soliris

PNH therapy Ultomiris (ravulizumab), which was granted an earlier than expected FDA approval last December. ... In trials, Ultomiris matched Soliris for efficacy – with a trend towards superiority – and offers improved dosing.
Alexion's Soliris adds new approval in rare disease NMOSD

The drug has already had its patent period extended in the US extended until 2027, giving Alexion significantly longer to ramp up sales of its successor treatment, Ultomiris, which gained FDA
CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

The CHMP recommended 13 medicines last Friday, including Ultomiris, Alexion’s follow-up to its rare disease blockbuster Soliris, and GSK’s single pill, two-drug HIV regimen, Dovato. ... A second-generation PNH therapy, Ultomiris has matched
Orphan drugs dominate FDA's record-breaking year

That included Alexion’s Ultomiris (ravulizumab) for paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease, which according to the FDA will “change the way that patients with PNH ... are treated.” Ultomiris need only

More from news
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

The forecast for 2023 sales is $1.97bn. Ultomiris (ravulizumab), from Alexion, treats paroxysmal nocturnal haemoglobinuria, a rare, potentially fatal blood disorder. ... Ultomiris received approval as an Orphan Drug from the FDA for adult patients with
Drug launches to watch in 2019

Analysts predict peak sales of up to $3bn. 5. Ultomiris – Alexion’s follow-up to Soliris. ... The follow-up, Ultomiris ALXN1210, is a second-generation PNH therapy with an NPV of $10.9bn.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...